Compare DAN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | HRMY |
|---|---|---|
| Founded | 1904 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2020 |
| Metric | DAN | HRMY |
|---|---|---|
| Price | $22.74 | $40.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $26.40 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.8M | 765.2K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.39 | ★ 3.17 |
| Revenue | ★ $9,957,000,000.00 | $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | $2.05 | $16.15 |
| P/E Ratio | $58.34 | ★ $12.79 |
| Revenue Growth | 17.78 | ★ 21.13 |
| 52 Week Low | $10.11 | $25.52 |
| 52 Week High | $23.24 | $40.93 |
| Indicator | DAN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 80.09 |
| Support Level | $22.05 | $38.12 |
| Resistance Level | $22.88 | $40.00 |
| Average True Range (ATR) | 0.78 | 1.20 |
| MACD | 0.06 | 0.25 |
| Stochastic Oscillator | 78.91 | 100.00 |
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.